Insights into ASX Stocks
Accent Group (ASX: AX1) — A Scaled Retailer Mispriced for What It Can Deliver
We continue to view Accent Group (AX1) as one of the few genuinely scaled, defensible retail platforms in Australia and New Zealand. In a sector where earnings volatility is the norm and brand power often trumps execution, AX1 stands out because it has quietly built a multi-brand ecosystem that gives it pricing control, data-driven consumer reach, and operational leverage that smaller retailers simply cannot replicate.
3 ASX Stocks with Bearish Charts, Which Can Go Much Lower!
In the current markets, even major players listed on the S&P/ASX 200 aren’t immune to caution flags on the charts. In this article, we'll examine three ASX-listed stocks whose price action suggests further downside may be ahead. We’ll look beyond the fundamentals and focus on technical signals: breakdowns below key moving averages, chart patterns like lower highs or descending triangles, and weakening momentum indicators.
BrainChip Holdings (ASX: BRN): High-Optionality Growth Play
BrainChip is a pioneer in ultra-low-power, neuromorphic AI processing, anchored by its Akida spiking neural network architecture. With US$13.5 million cash as of June 2025, the company is funding aggressive commercialisation efforts, including next-gen Akida 2.0, Pico devices, and defence / edge-AI partnerships. While financial performance is still pre-profit, recent commercial wins, deep IP protection, and product roadmap momentum provide compelling optional upside. Key risks include cash burn, technology adoption, and scaling edge-AI deployments.
European Lithium (ASX: EUR) — the Push toward European Lithium Independence
European Lithium is positioning itself as a future supplier of battery-grade lithium to Europe, with the Wolfsberg Project in Austria advancing through permitting, engineering, and early-stage financing activities.
Macroeconomic Report for Week Ending 21 Nov 2025 – Australian Market Outlook
The global macroeconomic backdrop shifted notably in the week ending 23 November 2025, contributing to a significant risk-off sentiment that heavily impacted Australian equities. In the United States, a mixed labour market report showing rising unemployment alongside stronger-than-expected job additions, combined with firm Services PMI data and Federal Reserve minutes signalling a delay in rate cuts, led to a repricing of interest rate expectations.
Racura Oncology (ASX: RAC) - A High-Risk, High-Reward Oncology Play
Racura Oncology (ASX: RAC) is executing on a bold clinical strategy centered on RC220 (bisantrene reformulation), targeting both cardioprotection and enhanced anticancer activity in combination with doxorubicin. The company has dosed its first patient in a Phase 1 solid tumor trial, expanded into South Korea, and strengthened its clinical leadership team, all while maintaining disciplined cash management (A$13.67m at June 2025) to fund operations into 2026. Though early-stage, RAC presents a compelling mid- to long-term optionality scenario for investors with conviction in cardio-oncology and specialty chemotherapy.